New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:08 EDTALR, RHHBY, DHR, ABTAlere CEO departure sharpens focus on potential acquisition, says JMP Securities
After the CEO of Alere, Ron Zwanziger, resigned, JMP Securities thinks the resignation "brings the notion of Alere's potential acquisition front and center." The firm sees Alere as "a natural fit" for Roche (RHHBY), Abbott (ABT), or Danaher (DHR).
News For ALR;RHHBY;DHR;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 20, 2014
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information
October 17, 2014
08:52 EDTDHRDanaher valuation remains attractive, says Bernstein
Subscribe for More Information
07:26 EDTDHRDanaher weakness a buying opportunity, says Argus
Subscribe for More Information
October 16, 2014
14:47 EDTRHHBYRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
13:13 EDTRHHBYRoche considers submitting Ebola test for emergency use approval, WSJ says
Subscribe for More Information
09:35 EDTRHHBYDiplomat announces contract to distribute Esbriet
Subscribe for More Information
06:05 EDTDHRDanaher sees Q4 EPS $1.00-$1.04, consensus $1.04
Included in this range is approximately $125M, or approximately 13c per diluted share, of anticipated productivity charges that are partially offset by an approximate 7c per diluted share anticipated gain on the sale of marketable securities. Thomas P Joyce, Jr., president and CEO, stated, "The Danaher team executed well, using the Danaher Business System to expand margins, generate strong cash flow performance, drive meaningful share gains and deliver better-than-expected earnings. As we plan for 2015, we remain mindful of the challenging macroeconomic outlook including the recently stronger dollar. However, we believe our focus on high-impact growth investments and margin expansion, combined with our robust balance sheet and M&A capacity, position us to finish 2014 well and drive long term results."
06:02 EDTDHRDanaher reports Q3 EPS 95c, consensus 89c
Subscribe for More Information
05:58 EDTRHHBYRoche sees FY14 core EPS targeted to grow ahead of sales
Subscribe for More Information
05:56 EDTRHHBYRoche reports 9 month revenue CHF34.76B vs. CHF34.87B last year
Roche CEO Severin Schwan said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets. We have had positive news from our product pipeline, including study results for Perjeta in breast cancer and a new combination therapy with Zelboraf in melanoma. The InterMune acquisition has also strengthened our portfolio with a new medicine, Esbriet for idiopathic pulmonary fibrosis, which has now been approved by the FDA. In Diagnostics, growth continues to be driven by the immunodiagnostics business and we have strengthened our molecular diagnostics portfolio with a new generation of testing systems.”
October 15, 2014
15:45 EDTRHHBYFDA approves Esbriet to treat idiopathic pulmonary fibrosis
Subscribe for More Information
15:28 EDTDHRNotable companies reporting before tomorrow's open
Subscribe for More Information
10:48 EDTABTShire tanks with AbbVie calling board meeting over merger
Subscribe for More Information
October 14, 2014
11:23 EDTRHHBYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
09:49 EDTDHRNetScout expects synergies to be achieved as both businesses are combined
Subscribe for More Information
07:31 EDTDHRNetScout to host conference call
Subscribe for More Information
06:55 EDTDHRDanaher sees Q3 adjusted EPS 90c, consensus 89c
Subscribe for More Information
06:49 EDTDHRDanaher to merge communications business with NetScout for $41.91 per share
Subscribe for More Information
06:48 EDTDHRNetScout Systems to acquire Danaher's Communications business for $2.6B
Subscribe for More Information
06:47 EDTDHRDanaher to merge communications business with NetScout for $41.91 per share
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use